Chronic administration of the soluble, nonbacterial fraction of kefir attenuates lipid deposition in LDLr−/− mice

Chronic treatment with a soluble nonbacterial fraction of kefir was able to decrease the lipid deposition in LDLr−/− hypercholesteremic mice, at least in part through modifying the circulating cytokine profile. The beneficial effects of kefir provide new perspectives for its use as an adjuvant in the prevention of atherosclerosis.